Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2016

Open Access 01-12-2016 | Research

Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients

Authors: Amélie Anota, Anne-Sophie Mariet, Philippe Maingon, Florence Joly, Jean-François Bosset, Anne-Valérie Guizard, Hugues Bittard, Michel Velten, Mariette Mercier

Published in: Health and Quality of Life Outcomes | Issue 1/2016

Login to get access

Abstract

Background

Health-related quality of life (HRQoL) has been positioned as one of the major endpoints in oncology. Thus, there is a need to validate cancer-site specific survey instruments. This study aimed to perform a transcultural adaptation of the 50-item Expanded Prostate cancer Index Composite (EPIC) questionnaire for HRQoL in prostate cancer patients and to validate the psychometric properties of the French-language version.

Methods

The EPIC questionnaire measures urinary, bowel, sexual and hormonal domains. The first step, corresponding to transcultural adaptation of the original English version of the EPIC was performed according to the back translation technique. The second step, comprising the validation of the psychometric properties of the EPIC questionnaire, was performed in patients under treatment for localized prostate cancer (treatment group) and in patients cured of prostate cancer (cured group). The EORTC QLQ-C30 and QLQ-PR25 prostate cancer module were also completed by patients to assess criterion validity. Two assessments were performed, i.e., before and at the end of treatment for the Treatment group, to assess sensitivity to change; and at 2 weeks’ interval in the Cured group to assess test-retest reliability. Psychometric properties were explored according to classical test theory.

Results

The first step showed overall good acceptability and understanding of the questionnaire. In the second step, 215 patients were included from January 2012 to June 2014: 125 in the Treatment group, and 90 in the Cured group. All domains exhibited good internal consistency, except the bowel domain (Cronbach’s α = 0.61). No floor effect was observed. Test-retest reliability assessed in the cured group was acceptable, expect for bowel function (intraclass coefficient = 0.68). Criterion validity was good for each domain and subscale. Construct validity was not demonstrated for the hormonal and bowel domains. Sensitivity to change was exhibited for 5/8 subscales and 2/4 summary scores for patients who experienced toxicities during treatment.

Conclusions

The French EPIC questionnaire seems to have adequate psychometric properties, comparable to those exhibited by the original English-language version, except for the construct validity, which was not available in original version.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
go back to reference Grosclaude P, Belot A, Daubisse Marliac L, Remontet L, Leone N, Bossard N, Velten M. Prostate cancer incidence and mortality trends in France from 1980 to 2011. Prog Urol. 2015;25:536–42.CrossRefPubMed Grosclaude P, Belot A, Daubisse Marliac L, Remontet L, Leone N, Bossard N, Velten M. Prostate cancer incidence and mortality trends in France from 1980 to 2011. Prog Urol. 2015;25:536–42.CrossRefPubMed
3.
go back to reference Parker WR, Montgomery JS, Wood Jr DP. Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner? Curr Opin Urol. 2009;19:303–8.CrossRefPubMed Parker WR, Montgomery JS, Wood Jr DP. Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner? Curr Opin Urol. 2009;19:303–8.CrossRefPubMed
4.
go back to reference Penson DF. Quality of life after therapy for localized prostate cancer. Cancer J. 2007;13:318–26.CrossRefPubMed Penson DF. Quality of life after therapy for localized prostate cancer. Cancer J. 2007;13:318–26.CrossRefPubMed
5.
go back to reference Lipscomb J, Donaldson MS, Arora NK, Brown ML, Clauser SB, Potosky AL, Reeve BB, Rowland JH, Snyder CF, Taplin SH. Cancer outcomes research. J Natl Cancer Inst Monogr. 2004;2004(33):178–97.CrossRef Lipscomb J, Donaldson MS, Arora NK, Brown ML, Clauser SB, Potosky AL, Reeve BB, Rowland JH, Snyder CF, Taplin SH. Cancer outcomes research. J Natl Cancer Inst Monogr. 2004;2004(33):178–97.CrossRef
6.
go back to reference Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep. 1985;69:1155–9.PubMed Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep. 1985;69:1155–9.PubMed
7.
go back to reference Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996;1996:7–9. Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996;1996:7–9.
8.
go back to reference Fayers PM, Machin D: Quality of life: the assessment, analysis and interpretation of patient-reported outcomes. England: John Wiley & Sons; 2013. Fayers PM, Machin D: Quality of life: the assessment, analysis and interpretation of patient-reported outcomes. England: John Wiley & Sons; 2013.
9.
go back to reference Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46:1417–32.CrossRefPubMed Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol. 1993;46:1417–32.CrossRefPubMed
10.
go back to reference van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418–24.CrossRefPubMed van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418–24.CrossRefPubMed
11.
go back to reference Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–12.CrossRefPubMed Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–12.CrossRefPubMed
12.
go back to reference Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.CrossRefPubMed Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.CrossRefPubMed
13.
go back to reference Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, Sanda MG. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20:557–66.CrossRefPubMed Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, Sanda MG. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20:557–66.CrossRefPubMed
14.
go back to reference Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000;25:3186–91.CrossRef Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000;25:3186–91.CrossRef
15.
go back to reference Wei JT. Scoring Instructions for the Expanded Prostate cancer Index Composite (EPIC). Ann Arbor. 2002;1001:48109–0330. Wei JT. Scoring Instructions for the Expanded Prostate cancer Index Composite (EPIC). Ann Arbor. 2002;1001:48109–0330.
16.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
17.
go back to reference Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, AobotEQoLG. B: EORTC QLQ-C30 Scoring Manual (3rd edition). Brussels: EORTC; 2001. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, AobotEQoLG. B: EORTC QLQ-C30 Scoring Manual (3rd edition). Brussels: EORTC; 2001.
18.
go back to reference Nunnally J, Bernstein I: Psychometric Theory (3) McGraw-Hill. New York: McGraw-Hill; 1994. Nunnally J, Bernstein I: Psychometric Theory (3) McGraw-Hill. New York: McGraw-Hill; 1994.
19.
go back to reference Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60:34–42.CrossRefPubMed Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60:34–42.CrossRefPubMed
20.
go back to reference Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef
21.
go back to reference Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.CrossRefPubMed Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.CrossRefPubMed
22.
go back to reference Floyd FJ, Widaman KF. Factor analysis in the development and refinement of clinical assessment instruments. Psychol Assess. 1995;7:286.CrossRef Floyd FJ, Widaman KF. Factor analysis in the development and refinement of clinical assessment instruments. Psychol Assess. 1995;7:286.CrossRef
23.
go back to reference Cohen J. Statistical power analysis for the behavioral sciences (revised ed.). New York: Academic; 1977. Cohen J. Statistical power analysis for the behavioral sciences (revised ed.). New York: Academic; 1977.
24.
go back to reference Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–8.CrossRefPubMed Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–8.CrossRefPubMed
25.
go back to reference Barry MJ, Fowler Jr FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association. J Urol. 1992;148:1558–63. discussion 1564.PubMed Barry MJ, Fowler Jr FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association. J Urol. 1992;148:1558–63. discussion 1564.PubMed
26.
go back to reference Barry MJ, Fowler Jr FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–57. discussion 1564.PubMed Barry MJ, Fowler Jr FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–57. discussion 1564.PubMed
27.
go back to reference Edelen MO, Reeve BB. Applying item response theory (IRT) modeling to questionnaire development, evaluation, and refinement. Qual Life Res. 2007;16 Suppl 1:5–18.CrossRefPubMed Edelen MO, Reeve BB. Applying item response theory (IRT) modeling to questionnaire development, evaluation, and refinement. Qual Life Res. 2007;16 Suppl 1:5–18.CrossRefPubMed
28.
go back to reference De Ayala RJ. The theory and practice of item response theory. New York: Guilford Press; 2009. De Ayala RJ. The theory and practice of item response theory. New York: Guilford Press; 2009.
29.
go back to reference Fischer GH, Molenaar IW: Rasch models: Foundations, recent developments, and applications. New York: Springer; 1995. Fischer GH, Molenaar IW: Rasch models: Foundations, recent developments, and applications. New York: Springer; 1995.
30.
go back to reference Bond T, Fox CM: Applying the Rasch model: Fundamental measurement in the human sciences. England: Routledge; 2015. Bond T, Fox CM: Applying the Rasch model: Fundamental measurement in the human sciences. England: Routledge; 2015.
Metadata
Title
Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients
Authors
Amélie Anota
Anne-Sophie Mariet
Philippe Maingon
Florence Joly
Jean-François Bosset
Anne-Valérie Guizard
Hugues Bittard
Michel Velten
Mariette Mercier
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2016
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-016-0571-y

Other articles of this Issue 1/2016

Health and Quality of Life Outcomes 1/2016 Go to the issue